Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Amorolfine→

Amorolfine Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
78613-35-1
Molecular formula
C21H35NO
Molecular weight
317.5 g/mol
Drug class
Morpholine antifungaltopical antimycotic
Mechanism of action
Inhibits fungal sterol biosynthesis, principally at Δ14-reductase and Δ7–Δ8-isomerase steps, reducing ergosterol and causing accumulation of abnormal sterols in the fungal cell membrane.
Indications / reported uses
  • Superficial fungal nail infections (onychomycosis)

Sources: UK SmPC (eMC) · PubMed pharmacology review

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Amorolfine Environmental Risk Assessment (ERA) (the Amorolfine ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.